Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression

Ha-Young Park, M.D.1, In-Jae Oh, M.D., Ph.D.1,2, Bo Gun Kho, M.D.1, Tae-Ok Kim, M.D.1, Hong-Joon Shin, M.D.1, Cheol Kyu Park, M.D., Ph.D.1,2, Yong-Soo Kwon, M.D., Ph.D.1, Yu-Il Kim, M.D., Ph.D.1, Sung-Chul Lim, M.D., Ph.D.1, Young-Chul Kim, M.D., Ph.D.1,2 and Yoo-Duk Choi, M.D., Ph.D.2,3

1Department of Internal Medicine, Chonnam National University Medical School, Gwangju, 2Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Hwasun, 3Department of Pathology, Chonnam National University Medical School, Gwangju, Korea

Background: Programmed death-ligand 1 (PD-L1), a transmembrane protein, binds to the programmed death-1 (PD-1) receptor, and anti–PD-1 therapy enables immune responses against tumors. This study aimed to assess clinical characteristics of PD-L1 expression using immunohistochemistry among Korean patients with lung cancer.

Methods: We retrospectively reviewed the data of patients with pathologically proven lung cancer from a single institution. PD-L1 expression determined by Tumor Proportion Score (TPS) was detected using 22C3 pharmDx (Agilent Technologies) and SP263 (Ventana Medical Systems) assays.

Results: From July 2016 to July 2017, 267 patients were enrolled. The main histologic type was adenocarcinoma (69.3%). Most participants were smokers (67.4%) and had clinical stage IV disease (60.7%). In total, 116 (42%) and 58 (21%) patients had TPS ≥1% and ≥50%, respectively. The patients were significantly older in TPS ≥1% group than in TPS <1% group (64.83±9.38 years vs. 61.73±10.78 years, p=0.014), not in TPS ≥50% cutoff value (64.69 ± 9.39 vs. 62.36 ± 10.51, p=0.178). Regarding histologic grade, higher proportions of poorly differentiated tumor were observed in the TPS ≥1% (40.8% vs. 25.8%, p=0.020) and TPS ≥50% groups (53.2% vs. 27.2%, p=0.004). Among 34 patients examined with 22C3 and SP263 assays, 27 had positive results in both assays, with a cutoff of TPS ≥1% (r=0.826; 95% confidence interval, 0.736–0.916).

Conclusion: PD-L1 expression, defined as TPS ≥1%, was related to older age and poorly differentiated histology. There was a similar distribution of PD-L1 expression in both 22C3 and SP263 results.

Keywords: Asian Continental Ancestry Group; Patients; Lung Neoplasms; Gene Expression; Carcinoma, Non-Small-Cell Lung

Introduction

Although many treatments have led to improved outcomes, lung cancer remains the leading cause of cancer-related mortality worldwide1,2. Immune checkpoint inhibitors provide new treatment options for many cancer patients. Programmed death-ligand 1 (PD-L1) is a transmembrane protein that binds to the programmed death-1 (PD-1) receptor. This interaction leads to inactivation of cytotoxic T cells and downregulation of the immune response, permitting cancer progression and metastasis. Blocking the PD-1/PD-L1 interaction between tumor cells and activated T-cells permits the immune system to remain active3,4. With the introduction of immune checkpoint in-
Inhibitors, the treatment for non-small cell lung cancer (NSCLC) is developing rapidly. Anti–PD-1 inhibitors (nivolumab and pembrolizumab) and anti–PD-L1 inhibitors (atezolizumab) have been approved as second-line treatments for patients with PD-L1 expression in advanced NSCLC in the United States, Europe, and Korea. The clinical characteristics of PD-L1 expression must be better understood, to be able to choose effective immune checkpoint inhibitors.

Although there is controversy regarding the use of PD-L1 as a predictive biomarker, until now the expression of PD-L1 had been thought to be the most valuable predictor of the response to anti-PD-1/PD-L1 inhibitors. Many PD-L1 inhibitors have been assessed with different immunohistochemical (IHC) assays using different antibodies, clones, platforms, scoring systems, and cutoff values. For example, the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies) and SP263 assay (Ventana Medical Systems) are approved as companion diagnostic tests for pembrolizumab. The PD-L1 IHC 28-8 pharmDx assay and SP263 have been used for nivolumab and the PD-L1 IHC SP142 assay for atezolizumab. Because there is a PD-L1 assay for each PD-1/PD-L1 inhibitor, many clinical trials have examined the correlation of PD-L1 expression with clinical outcomes. A blueprint project assessing the analytic comparability among 22C3, 28-8, SP263, and SP142 showed that three assays (excluding SP142) were closely aligned on tumor cell staining.

In previous studies, several clinicopathologic variables have been found to be correlated with PD-L1 expression, such as age, histology, degree of differentiation, and lymph node metastasis. One study reported that the expression of PD-L1 was significantly higher for women, never smokers, and in adenocarcinoma. To clarify these discordant study results, the present study aimed to investigate the clinical and pathologic characteristics of PD-L1 expression in Korean patients with lung cancer who might be candidates for immunotherapy. We also examined the correlation between PD-L1 IHC 22C3 and SP263 data to assess the possibility of using these PD-L1 tests interchangeably.

**Materials and Methods**

1. **Patients and materials**

We retrospectively reviewed the clinical and pathologic data of patients with pathologically proven lung cancer from a single institution between July 2016 and July 2017. A total of 267 patients with formalin-fixed, paraffin-embedded tissue samples were included. All data were gathered in accordance with the amended Declaration of Helsinki, following approval of the study by an independent hospital institutional review board (IRB approval number: CNUHH-2018-020). The need for written informed consent was waived because of the retrospective design of the study.

2. **Immunohistochemistry**

PD-L1 expression was detected using qualitative IHC stain-

| Table 1. Baseline demographics |
|-----------------------------|
| **Characteristic** | **No. (%) (n=267)** |
| Age, median (range), yr | 64 (24–82) |
| **Sex** | |
| Male | 191 (71.5) |
| Female | 76 (28.5) |
| **Smoking history** | |
| Never | 87 (32.6) |
| Former | 83 (31.3) |
| Current | 97 (36.3) |
| **Histologic type** | |
| Adenocarcinoma | 185 (69.3) |
| Squamous cell carcinoma | 73 (27.7) |
| Others* | 8 (3) |
| **Biopsy method** | |
| Operation | 71 (26.6) |
| Small biopsy† | 192 (71.9) |
| Cytology | 4 (1.5) |
| **Histologic grade** | |
| Well differentiated | 54 (20.2) |
| Moderately differentiated | 76 (28.5) |
| Poorly differentiated | 74 (27.7) |
| Others‡ | 23 (8.6) |
| **EGFR mutation** | |
| Wild type | 153 (57.3) |
| Mutated | 65 (24.3) |
| Not checked | 58 (17.6) |
| **ALK FISH** | |
| Negative | 93 (34.8) |
| Positive | 17 (6.4) |
| Not checked | 157 (58.8) |

*Other types consisting of small cell lung cancer (5 cases) and large cell lung cancer (3 cases). Small biopsy specimens were collected via bronchoscopy, endobronchial ultrasound-transbronchial needle aspiration, or transthoracic needle biopsy of the lung. †Others included specimens for which histologic grade could not be checked. EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; FISH: fluorescence in situ hybridization.
ing with the in vitro diagnostic PD-L1 IHC 22C3 pharmDx test on the Dako Autostainer (Agilent Technologies, Santa Clara, CA; Dako, Carpinteria, CA, USA) and the in vitro diagnostic PD-L1 IHC SP263 test on the Ventana BenchMark platform (Ventana Medical Systems, Tucson, AZ, USA) by one pathologist. The 22C3 pharmDx assay was performed for all patients, and both assays were carried out for 34 patients.

For the 22C3 pharmDx assay, sections were stained with anti–PD-L1 22C3 mouse monoclonal primary antibody using the EnVision FLEX visualization system on a Dako Autostainer Link 48 system with negative reagent controls and cell line run controls, as described in the PD-L1 IHC 22C3 pharmDx package insert. Deparaffinization, rehydration, and target retrieval was performed with a 3-in-1 procedure using PT Link. Following peroxidase blocking, specimens were incubated with monoclonal mouse primary antibody to PD-L1 or the negative control reagent. Specimens were then incubated with Mouse Linker, followed by incubation with

Table 2. Clinical and pathological characteristics of the 267 patients with PD-L1 expression

| Characteristic       | PD-L1 TPS ≥1% (n=116) | TPS <1% (n=151) | p-value | PD-L1 TPS ≥50% (n=58) | TPS <50% (n=209) | p-value |
|----------------------|------------------------|------------------|---------|------------------------|------------------|---------|
| Age, yr              | 64.83±9.38             | 61.73±10.78      | 0.014   | 64.69±9.39             | 62.36±10.51      | 0.178   |
| Sex                  |                        |                  |         |                        |                  |         |
| Male                 | 87 (75.0)              | 104 (68.9)       | 0.743   | 43 (74.1)              | 148 (70.8)       |         |
| Female               | 29 (25.0)              | 47 (31.1)        | 0.191   | 15 (25.9)              | 61 (29.2)        |         |
| Smoking              |                        |                  |         |                        |                  |         |
| Never smoker         | 35 (30.2)              | 52 (34.4)        | 0.102   | 19 (32.8)              | 68 (32.5)        |         |
| Ex-smoker            | 44 (37.9)              | 39 (25.8)        |         | 23 (39.7)              | 60 (28.7)        |         |
| Current smoker       | 37 (31.9)              | 60 (39.7)        |         | 16 (27.6)              | 81 (38.8)        |         |
| Histologic type      | 0.082                  |                  |         | 0.012                  |                  |         |
| SQC                  | 34 (29.6)              | 38 (25.3)        |         | 13 (22.4)              | 59 (28.5)        |         |
| ADC                  | 78 (67.8)              | 107 (71.3)       |         | 42 (72.4)              | 143 (69.1)       |         |
| Others*              | 3 (2.6)                | 5 (3.3)          |         | 3 (4.1)                | 5 (2.4)          |         |
| Biopsy method        | 0.853                  |                  |         | 0.298                  |                  |         |
| Operation            | 29 (25.0)              | 42 (27.8)        |         | 13 (22.4)              | 58 (27.8)        |         |
| Small biopsy†        | 85 (73.3)              | 107 (70.0)       |         | 43 (74.1)              | 149 (71.3)       |         |
| Cytology             | 2 (1.7)                | 2 (1.7)          |         | 2 (3.4)                | 2 (1.0)          |         |
| Histologic grade     | 0.020                  |                  |         | 0.004                  |                  |         |
| Well differentiated   | 16 (15.5)              | 38 (30.6)        |         | 5 (10.6)               | 49 (27.7)        |         |
| Moderately differentiated | 33 (32.0)  | 43 (34.7)        |         | 12 (25.5)              | 64 (35.6)        |         |
| Poorly differentiated | 42 (40.8)              | 32 (25.8)        |         | 25 (53.2)              | 49 (27.2)        |         |
| Others‡              | 12 (11.7)              | 11 (8.9)         |         | 5 (10.6)               | 18 (10.0)        |         |
| *EGFR mutation (n=218) | 0.901                |                  |         | 0.888                  |                  |         |
| Wild type            | 62 (67.4)              | 91 (72.8)        |         | 33 (67.3)              | 120 (71.4)       |         |
| Mutated              | 30 (32.7)              | 34 (27.2)        |         | 16 (32.3)              | 48 (28.6)        |         |
| *ALK FISH (n=110)    | 0.793                  |                  |         | 0.234                  |                  |         |
| Negative             | 44 (83.0)              | 49 (86.0)        |         | 23 (76.7)              | 70 (87.5)        |         |
| Positive             | 9 (17.0)               | 8 (14.0)         |         | 7 (23.3)               | 10 (12.5)        |         |

Values are presented as mean±SD or number (%).

*Other types included small cell lung cancer (5 cases) and large cell lung cancer (3 cases).
†Small biopsy specimens were collected via bronchoscopy, endobronchial ultrasound-trans-bronchial needle aspiration, or transthoracic needle biopsy of the lung. "Others" included specimens for which histologic grade could not be checked.

PD-L1: programmed death-ligand 1; TPS: Tumor Proportion Score; SQC: squamous cell carcinoma; ADC: adenocarcinoma; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; FISH: fluorescence in situ hybridization; SD: standard deviation.
a ready-to-use visualization reagent consisting of secondary antibody molecules and horseradish peroxidase molecules coupled to a dextran polymer backbone. The enzymatic conversion of the subsequently added chromogen results in the precipitation of a visible reaction product at the site of the antigen. The color of the chromogenic reaction is modified using a chromogen enhancement reagent; the specimen may then be counterstained and cover slipped. Results were interpreted using a light microscope.

For SP263 assay, sections were stained with anti–PD-L1 SP263 rabbit monoclonal primary antibody and a matched rabbit immunoglobulin G–negative control, using an OptiView DAB IHC Detection Kit (Ventana Medical Systems) on the BenchMark ULTRA automated staining platform. Detection and quantification of the percentage of immunoreactive tumor cells was performed according to the manufacturer’s recommendations. Briefly, neoplastic cells were considered positive when any cell membrane staining was present, ignoring pure cytoplasmic immunoreaction. Staining of immune cells was also disregarded. PD-L1 protein expression was determined using the Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining. A specimen was considered PD-L1 positive with ≥50% of viable tumor cells exhibiting membrane staining at any intensity (i.e., TPS ≥50%); a weak PD-L1-positive result is 1%≤TPS<50%. We designated two categories according to cutoffs of TPS 1% or 50%.

3. Statistical analyses

Clinical characteristics and associations with biomarkers were examined by comparing differences using the Fisher exact test or independent sample t test, as appropriate. To evaluate the relationship between PD-L1 expression levels ascertained with the 22C3 and SP263 assays, we investigated 34 samples using precision analysis with Pearson’s concordance correlation coefficient. A p-value of <0.05 was considered significant. Statistical analysis was performed using IBM SPSS version 23 (IBM Corp., Armonk, NY, USA).

Results

1. Baseline demographics

A total of 267 patients were included in this study (Table 1); median age was 64 years (range, 24–82 years). Most patients were male (n=191, 71.5%) and former (n=83, 31.3%) or current smokers (n=97, 36.3%). The most frequent histologic type was adenocarcinoma (n=185, 69.3%), followed by squamous cell carcinoma (n=73, 27.7%) and small cell lung cancer (n=5, 1.9%). Most patients had clinical stage IV disease (n=162, 60.7%). Some patients were analyzed for the presence of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement: the result showed 65 patients (24.3%) with EGFR mutation and 17 (6.4%) with ALK rearrangement. Most specimens were obtained by small biopsy (n=192, 71.9%), followed by operation (n=71, 26.6%). The histologic grade included moderately differentiated (n=76, 28.5%), poorly differentiated (n=74, 27.7%), and well differentiated (n=54, 20.2%).

2. Characteristics of patients with PD-L1 expression

PD-L1 was evaluated in 267 patients, categorized using cutoffs of TPS 1% or 50% (Table 2, Figure 1). There were 116 (42%) and 58 (21%) patients with TPS ≥1% and ≥50%, respectively. The correlation between age and PD-L1 expression was not significant (p=0.097). But the patients in the TPS ≥1% group were older than those in the TPS <1% group (64.83±9.38 vs. 61.73±10.78, p=0.014). Furthermore, the patients in the TPS ≥50% group were older than those in the TPS <50% group, but this was not statistically significant (64.69±9.39 vs. 62.36±10.51, p=0.178). The group with TPS ≥1% included patients with ad-
enocarcinoma (n=78, 67.8%) and squamous cell carcinoma (n=34, 29.6%) histology. The TPS ≥50% group also included patients with adenocarcinoma (n=42, 72.4%) and squamous cell carcinoma (n=13, 22.4%). The rate of poorly differentiated pathology was significantly higher in patients with TPS ≥1% (40.8% vs. 25.8%, p=0.020) and TPS ≥50% (53.2% vs. 27.2%, p=0.004) than their counterparts. There were no differences with respect to smoking, EGFR mutation, ALK rearrangement status, or biopsy site.

3. Relationship between 22C3 and SP263

Among the 34 patients analyzed using both the 22C3 and SP263 assays, 27 patients had positive results in both assays, with a cutoff of 1% or higher (Figure 2A) and 20 patients had positive with a cutoff of 50% or higher (Figure 2B). There was a similar distribution between the 22C3 and SP263 assays as-says (r=0.826; 95% confidence interval, 0.736–0.916) (Figure 3A). But it didn’t show a complete correlation between two assays for each patient (Figure 3B).

Discussion

In this study, we explored the clinicopathologic characteristics of PD-L1–positive Korean patients with lung cancer. For all enrolled patients, we performed PD-L1 IHC assays using monoclonal mouse anti–PD-1, clone 22C3; PD-L1 expression was described using TPS. A total 42% of patients were PD-L1 positive using a cutoff of TPS ≥1%; this proportion was 21% with a cutoff of TPS ≥50%. Patients in the PD-L1-positive (cutoff TPS ≥1%) group were significantly older than those in the PD-L1-negative group. But in cutoff TPS ≥ 50% group, the patients were older than those in the TPS <50% group, but this was not statically significant. This seems to be due to the small sample size of the TPS ≥50% group to obtain statistical significance. The most frequent histologic grade was poorly differentiated type in both the TPS ≥1% and TPS ≥50% groups.

In previous studies, several clinicopathologic variables were found to be correlated with PD-L1 expression, but there were discordant results among these studies. Mu et al.12 evaluated 109 patients with adenocarcinoma and estimated the association between expressed PD-L1 and tumor histologic type, degree of differentiation, and lymph node metastasis. Those authors found that higher expression of PD-L1 was related to adenocarcinoma histology and overall survival12. Velchetti et al.18 explored cases of NSCLC including 340 cases in Greece and 204 cases from Yale University in the U.S. They found

![Figure 2](image1.png)

![Figure 3](image2.png)
that advanced stage and squamous cell carcinoma were correlated with high PD-L1 expression. Cooper et al.13 analyzed 678 tissue samples from patients with stage I–III NSCLC and 52 paired nodal metastases. The authors showed that younger patients and those with poor differentiation were associated with high PD-L1 expression; there was no association with sex, tumor size, stage, nodal status, or EGFR or KRAS mutation status.13 Azuma et al.14 evaluated 164 specimens of surgically resected NSCLC and found that the expression of PD-L1 was significantly higher in women, never smokers, and patients with adenocarcinoma. These inconsistent results suggest that PD-L1 expression might differ by race or residence, and it may be necessary to analyze the clinical characteristics of each group.

We also examined the relationship between IHC assays in 34 patients and found a similar distribution of PD-L1 expression between the 22C3 pharmDx and SP263 assays. Although there has been some controversy regarding use of PD-L1 as a predictive biomarker, the expression of PD-L1 has been thought to be the most valuable predictor of response to anti-PD-L1 antibody. Many PD-L1 inhibitors have been assessed with different IHC assays using different antibodies, clones, platforms, scoring systems, and cutoff values. For example, the 22C3 pharmDx and SP263 assay are approved as companion diagnostic tests for pembrolizumab. The 28-8 pharmDx and SP263 assay have been used for nivolumab and the SP142 assay for atezolizumab.

Because there is an PD-L1 assay for each PD-1/PD-L1 inhibitor, many clinical trials have examined the correlation of PD-L1 expression with clinical outcomes. A blueprint project assessed analytic comparability among the 22C3, 28-8, SP263, and SP142 assays using 39 NSCLC tumor samples. The result showed that three assays (excluding SP142) were closely aligned on tumor cell staining.11 In a harmonized trial, 15 lung cancer resection specimens were used to assess interobserver concordance and PD-L1 IHC patterns using the 28-8, 22C3, SP142, and SP263 assays. The result showed that the 22C3 and SP263 assays could be used interchangeably. However, a large-scale multicenter study is needed to better understand PD-L1 expression in lung cancer.

In conclusion, this retrospective study demonstrated that Korean patients with lung cancer who had PD-L1 expression (TPS ≥1%) were older and had poorly differentiated histology. Patients with these characteristics, use of the PD-L1 IHC assay should be actively considered. We also found that the 22C3 pharmDx and SP263 assays could be used interchangeably. However, a large-scale multicenter study is needed to confirm these results.

Authors’ Contributions

Conceptualization: Oh IJ, Park HY. Methodology: Oh IJ, Choi YD. Formal analysis: Park HY, Oh IJ, Choi YD. Data curation: Park HY, Oh IJ, Kho BG, Kim TO, Shin HJ, Park CK, Kim YC. Software: Park HY. Validation: Oh IJ. Investigation: Park HY, Oh IJ, Park CK, Kim YC, Kwon YS, Kim YI, Lim SC. Writing - original draft preparation: Park HY. Writing - review and editing: Oh IJ, Park CK, Kim YC. Approval of final manuscript: all authors.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

This work was supported by a clinical research grant from Chonnam National University Hwasun Hospital 2017.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7-30.
2. Park JY, Jang SH. Epidemiology of lung cancer in Korea: re-
cent trends. Tuberc Respir Dis 2016;79:58-69.
3. Kweon SS. Updates on cancer epidemiology in Korea, 2018. Chonnam Med J 2018;54:90-100.
4. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
5. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GI, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009;206:3015-29.
6. Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 2016;375:1767-78.
7. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy: inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012;18:6580-7.
8. Hall RD, Gray JE, Chiappori AA. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control 2013;20:22-31.
9. Grigg C, Rizvi NA. PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? J Immunother Cancer 2016;4:48.
10. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015;14:847-56.
11. Hirsch FR, McElhinney A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 2017;12:208-22.
12. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011;28:682-8.
13. Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer 2015;89:181-8.
14. Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non-small-cell lung cancer. Ann Oncol 2014;25:1935-40.
15. Roach C, Zhang N, Corigliano E, Jansson M, Tolan G, Ponto G, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol 2016;24:392-7.
16. Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol 2016;11:95.
17. Marchetti A, Barberis M, Franco R, De Luca G, Pace MV, Staihano S, et al. Multicenter comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) assays to test PD-L1 expression for NSCLC patients to be treated with immune checkpoint inhibitors. J Thorac Oncol 2017;12:1654-63.
18. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Szol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014;94:107-16.
19. Scheel AH, Dietel M, Heukamp LC, Johrens K, Kirchner T, Reu S, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 2016;29:1163-72.
20. Adam J, Rouquette I, Damotte D, Badoual C, Danel C, Damia-la F, et al. PI.04a.04: multicentric French harmonization study for PD-L1 IHC testing in NSCLC. J Thorac Oncol 2017;12(Suppl):S1-2.
21. Ratcliffe MJ, Sharpe A, Midha A, Barker C, Scott M, Scorer P, et al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clin Cancer Res 2017;23:3585-91.